CN103554123B - Containing chromone structure pyrazoles norcantharidin derivative and preparation method thereof and application - Google Patents
Containing chromone structure pyrazoles norcantharidin derivative and preparation method thereof and application Download PDFInfo
- Publication number
- CN103554123B CN103554123B CN201310574585.3A CN201310574585A CN103554123B CN 103554123 B CN103554123 B CN 103554123B CN 201310574585 A CN201310574585 A CN 201310574585A CN 103554123 B CN103554123 B CN 103554123B
- Authority
- CN
- China
- Prior art keywords
- chromone
- norcantharidin
- pyrazoles
- preparation
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention discloses a kind of novel containing chromone structure pyrazoles norcantharidin derivative and preparation method thereof and application, this preparation method 1,3-dipole-diople interaction method C in Norcantharidin structure
5and C
6pyrazole ring is introduced in position, react import chromone structure with chromone derivative, thus synthesizes a series of totally 6 novel pyrazoles lopps norcantharidin derivatives containing chromone structure, improves the activity of Norcantharidin.Gained of the present invention is applied to the synthesis of synthesizing antineoplastic medicament containing chromone structure pyrazoles norcantharidin derivative, is with a wide range of applications.
Description
Technical field
The invention belongs to technical field of norcantharidin derivative, particularly relate to one containing chromone structure pyrazoles norcantharidin derivative and preparation method thereof and application.
Background technology
Norcantharidin, chemical name: 7-oxabicyclo [2.2.1] heptane-2,3-dicarboxylic anhydride, CAS:[5442-12-6; 29745-04-8], chemical structural formula is as follows:
Cantharidin is the effective ingredient of research malignant tumor medicine.Modern study proves, it has certain curative effect to primary hepatocarcinoma, and has leukocyte increasing, not the advantage such as Immunosuppression system, therefore, has very high with researching value, causes the extensive concern of people.But the toxicity of Cantharidin is larger, synthesize very complicated, recent research shows, 2 have been lacked in Norcantharidin, two methyl of 3, Norcantharidin not only maintains stronger anti-tumor activity and unique function of increasing leukocyte, and toxicity reduces greatly, substantially eliminates Cantharidin and swashs side effect to urinary system telson.
Therefore, relevant with a Cantharidin backbone modification synthetic work be significant removes prosposition methyl substituted.This structural modification can not affect Cantharidin antitumour activity and toxicity decreases, and synthesis step simplifies.
Summary of the invention
The object of this invention is to provide one containing chromone structure pyrazoles norcantharidin derivative, especially by use 6-methyl substituted chromone phenylhydrazone, structure of modification is carried out to Norcantharidin, application 1,3-dipole-diople interaction method introduces five-ring pyrazoles and chromone structure, improves the activity of Norcantharidin.
In order to solve the problems of the technologies described above, the present invention is solved by following technical proposals:
A kind of containing chromone structure pyrazoles norcantharidin derivative, its general structure is as follows:
Wherein, R
1for H, OH, CH
3, NO
2, Cl or Br.
The above-mentioned preparation method containing chromone structure pyrazoles norcantharidin derivative, comprises the following steps:
(1) synthesis of dehydronorcantharidiimide element: by MALEIC ANHYDRIDE porphyrize, add ether, is stirred to dissolving under room temperature condition, instillation furans, stirring at room temperature 24 ~ 48 hours, there is Diels-Alder and react in furans and MALEIC ANHYDRIDE, filtration under diminished pressure obtains dehydronorcantharidiimide element;
(2) synthesis of N-substituted dehydronorcantharidiimide imide: be dissolved in in acetone solvent by dehydronorcantharidiimide element, under agitation drips the acetone soln of aniline, reacts and adds manganese acetate, triethylamine and aceticanhydride after 1 hour, at room temperature reacts 8 hours; Dried precipitation is dissolved in dimethyl formamide, with dicyclohexylcarbodiimide stirring reaction 10 hours in ice-water bath (temperature is down to 0 DEG C), filtrate is placed in frozen water and obtains crystallization, then recrystallization obtains product;
(3) chromone structure is imported: be dissolved in sewage ethanol by N-substituted dehydronorcantharidiimide imide and 6-methyl substituted chromone phenylhydrazone, add chloramine-T, reflux 12 hours, carry out 1, the addition reaction of 3-dipole-diople interaction, import chromone and pyrrazole structure, use methyl alcohol recrystallize, vacuum-drying obtains compound;
Wherein, the preparation method of 6-methyl substituted chromone phenylhydrazone is as follows: get phenylhydrazine and add and fill in the flask of tetrahydrofuran (THF), boiling water bath return stirring is to dissolving, then the ethanol solution being dissolved with 6-methyl-chromone is slowly added dropwise to, continue boiling water bath return stirring, drip concentrated hydrochloric acid, there is pale yellow precipitate to occur, continuous boiling water bath return stirring 5h, stop water-bath, add distilled water to stir, pale yellow precipitate darkens, and suction filtration obtains phenylhydrazone, yellowish red color needle-like product, rinse repeatedly with anhydrous diethyl ether, vacuum-drying obtains product 6-methyl-chromone phenylhydrazone.
Gained of the present invention is mainly used in synthesizing antineoplastic medicament aspect containing chromone structure pyrazoles norcantharidin derivative.
The reaction that the present invention relates to is as follows:
3aR
1hydrogen; 3bR
1it is hydroxyl; 3cR
1it is methyl; 3dR
1it is nitro; 3eR
1chlorine; 3fR
1it is bromine
.
4aR
1hydrogen; 4bR
1it is hydroxyl; 4cR
1it is methyl; 4dR
1it is nitro; 4eR
1chlorine; 4fR
1it is bromine
.
Research finds, the oxygen in Norcantharidin five-ring can replace with nitrogen or sulfo-, and some substituting groups can be substituted on nitrogen and sulphur.Simultaneously at C
5and C
6that upper replacement can also change pharmacologically active.We draw following experimental data through research work for this reason:
The present invention, owing to have employed above technical scheme, has significant technique effect:
The basis that the present invention introduces pyrazoles on C-5 or C-6 has also imported the structure of chromone, 6-methyl substituted chromone phenylhydrazone is used to carry out structure of modification to Norcantharidin, ingenious application 1,3-dipole-diople interaction method introduces five-ring pyrazoles and chromone structure, improves the activity of Norcantharidin.
Embodiment
Below in conjunction with specific embodiment, the present invention is described in further detail:
The general structure of the raw material of the inventive method synthesis norcantharidin derivative is as shown below:
Compound 5 is chromone derivative, is that 6-methyl substituted chromone and phenylhydrazine react the hydrazone generated.
The synthesis of 6-methyl-chromone phenylhydrazone adopts chromone and phenylhydrazine dehydration reaction to generate the method for Schiff's base
Concrete operations: the phenylhydrazine getting 2mmol adds in the flask filling 10mL tetrahydrofuran (THF), boiling water bath return stirring, to dissolving, is then slowly added dropwise to the ethanol solution that 20mL is dissolved with 2mmol6-methyl-chromone, continues boiling water bath return stirring 1h, drip 10 hydrochloric acid, have pale yellow precipitate to occur.Continuous boiling water bath return stirring 5h, stops water-bath, and add 20mL distilled water and stir, pale yellow precipitate darkens, and suction filtration obtains phenylhydrazone, yellowish red color needle-like product.Rinse repeatedly with anhydrous diethyl ether, vacuum-drying obtains product 6-methyl-chromone phenylhydrazone.
Embodiment 1
Containing chromone structure pyrazoles norcantharidin derivative, its general structure is as follows:
Wherein, R
1for H, OH, CH
3, NO
2, Cl or Br.
The above-mentioned preparation method containing chromone structure pyrazoles norcantharidin derivative, comprises the steps:
1): the synthesis of dehydronorcantharidiimide element: add 15mL ethyl ester successively in 100mL Erlenmeyer flask, 4.00g (40mmol) Powdered MALEIC ANHYDRIDE.After MALEIC ANHYDRIDE dissolving, under stirring, add 2.76g (40.5mmol) furans.And then ambient temperatare puts 24-48 hour, the product obtained after reacting completely is carried out filtration under diminished pressure and obtains Norcantharidin.
2): the synthesis of N-substituted dehydronorcantharidiimide imide: get 3.32g (20mmol) Norcantharidin and be dissolved in 30mL acetone, acetone soln and aniline are joined in reaction Erlenmeyer flask, have a large amount of precipitations to generate as seen.React at normal temperatures after 8 hours, by sedimentation and filtration, out final vacuum is dry, is dissolved in 20mL dimethyl formamide, is cooled to 0 DEG C.Be placed in ice-water bath, add 3.09g (15mmol) dicyclohexylcarbodiimide, stirring reaction 10 hours.Then cool, filter, filtrate is poured in 50mL frozen water, separate out solid.Filtered, washing, finally obtains product 3a-3f by recrystallizing methanol.
3): by 1mmolN-substituted dehydronorcantharidiimide imide and 1.1mmol6-methyl-chromone phenylhydrazone in 20mL alcohol, then add 1.2mL chloramine-T, reflux 12 hours.By sedimentation and filtration, cleaning, uses methyl alcohol recrystallize, obtains these 6 products of product 4a, 4b, 4c, 4d, 4e, 4f after vacuum-drying.
Experimental data is as follows:
(3aR, 4S, 4aR, 7aS, 8S, 8aR)-6-(phenyl)-4,8-epoxy-1-phenyl-3-(quinoxaline)-4,4a, 6,7a, 8,8a-six hydrogen [3,4-f] indazole-5,7 (1H, 3aH)-diketone (4a)
m.p.91.8-92.691.3-92.5℃
1HNHR(DMSO)δ:2.44(s,3H,CH
3),7.26(s,1H,O＝C-H),7.29-7.83(m,13H,Ar-H),2.10(s,1H,C
6-H),2.71(s,1H,C
5-H),4.27(s,1H,C
4-H),3.85(s,1H,C
3-H),3.02(s,1H,C
2-H),3.58(s,1H,C
1-H).IR3445(N-C＝O),1714(C＝O),1416(C＝N),1159(C-O-C)cm
-1
Anal.calcd.forC
31H
23N
3O
5.C,71.80；H,4.45；N,8.12.
(3aR, 4S, 4aR, 7aS, 8S, 8aR)-6-(4-hydroxyphenyl)-4,8-epoxy-1-phenyl-3-(6-methyl-4H-chromone-4-ketone)-4,4a, 6,7a, 8,8a-six hydrogen [3,4-f] indazole-5,7 (1H, 3aH)-diketone (4b)
m.p.106.5-108.9106.9-109.3107.2-110.1℃
1HNHR(DMSO)δ:2.44(s,3H,CH
3),7.57(s,1H,O＝C-H),7.17-7.83(m,12H,Ar-H),2.11(s,1H,C
6-H),3.02(s,1H,C
5-H),4.27(s,1H,C
4-H),3.85(s,1H,C
3-H),3.02(s,1H,C
2-H),3.58(s,1H,C
1-H),5.40(s,1H,OH).
IR3417(N-C＝O),1558(C＝N),1716(C＝O),1249(C-O-C)cm
-1
Anal.calcd.forC
31H
23N
3O
6.C,69.78；H,4.36；N,7.90.
(3aR, 4S, 4aR, 7aS, 8S, 8aR)-6-(4-p-tolyl)-4,8-epoxy-1-phenyl-3-(6-methyl-4H-chromone-4-ketone)-4,4a, 6,7a, 8,8a-six hydrogen [3,4-f] indazole-5,7 (1H, 3aH)-diketone (4c)
m.p.>220℃
1HNHR(DMSO)δ:2.20(s,6H,CH
3),7.26(s,1H,O＝C-H),6.85-7.62(m,13H,Ar-H),1.61(s,1H,C
6-H),3.03(s,1H,C
5-H),4.84(s,1H,C
4-H),4.28(s,1H,C
3-H),4.30(s,1H,C
2-H),4.33(s,1H,C
1-H).
IR3452(N-C＝O),1705(C＝N),1557(C＝O),1242(C-O-C)cm
-1
Anal.calcd.forC
32H
25N
3O
5.C,72.30；H,4.72；N,7.92.
(3aR, 4S, 4aR, 7aS, 8S, 8aR)-6-(4-nitrophenyl)-4,8-epoxy-1-phenyl-3-(6-methyl-4H-chromone-4-ketone)-4,4a, 6,7a, 8,8a-six hydrogen [3,4-f] indazole-5,7 (1H, 3aH)-diketone (4d)
m.p.107.8-113.2107.1-114.3107.8-115.2℃
1HNHR(DMSO)δ:2.44(s,3H,CH3),7.26(s,1H,O＝C-H),6.62-8.09(m,7
H,Ar-H),2.10(s,1H,C
6-H),2.71(s,1H,C
5-H),4.27(s,1H,C
4-H),3.85(s,1H,C
3-H),3.02(s,1H,C
2-H),3.58(s,1H,C
1-H).
IR3260(N-C＝O),3048(ArH),1597(C＝N),1717(C＝O),1270(C-O-C)cm
-1
Anal.calcd.forC
31H
22N
4O
7.C,66.20；H,3.93；N,8.60.
(3aR, 4S, 4aR, 7aS, 8S, 8aR)-6-(4-chloro-phenyl-)-4,8-epoxy-1-phenyl-3-(6-methyl-4H-chromone-4-ketone)-4,4a, 6,7a, 8,8a-six hydrogen [3,4-f] indazole-5,7 (1H, 3aH)-diketone (4e)
m.p.105.1-106.8105.7-107.3105.4-107.5℃
1HNHR(DMSO)δ:2.44(s,3H,CH
3),7.26(s,1H,O＝C-H),6.41-7.82(m,13H,Ar-H),2.10(s,1H,C
6-H),3.03(s,1H,C
5-H),4.84(s,1H,C
4-H),4.28(s,1H,C
3-H),4.30(s,1H,C
2-H),4.33(s,1H,C
1-H).
IR3358(N-C＝O),3078(ArH),1598(C＝N),1707(C＝O),1261(C-O-C)cm
-1
Anal.calcd.forC
31H
22ClN
3O
5.C,67.45；H,4.04；N,7.62.
(3aR, 4S, 4aR, 7aS, 8S, 8aR)-6-(4-bromophenyl-hydrazine)-4,8-epoxy-1-phenyl-3-(6-methyl-4H-chromone-4-ketone)-4,4a, 6,7a, 8,8a-six hydrogen [3,4-f] indazole-5,7 (1H, 3aH)-diketone (4f)
m.p.85.2-86.186.3-87.286.6-87.9℃
1HNHR(DMSO)δ:2.44(s,3H,CH3),7.23(s,1H,O＝C-H),6.38-7.82(m,13H,Ar-H),2.11(s,1H,C
6-H),3.01(s,1H,C
5-H),4.84(s,1H,C
4-H),4.28(s,1H,C
3-H),4.30(s,1H,C
2-H),4.33(s,1H,C
1-H).
IR:3442(N-C＝O),1560(C＝N),1706(C＝O),1238(C-O-C)cm
-1
Anal.calcd.forC
31H
22BrN
3O
5.C,62.44；H,3.71；N,7.03.
The antitumor cytolytic activity result of above-mentioned norcantharidin derivative
Mtt assay measures the In-vitro Inhibitory Effect of three series compounds to different knurl strain:
Compound DMSO is dissolved, dilution, tumour cell SMMC-7721 (human liver cancer cell), KB (cancer cell of oral cavity), SGC7901 (stomach cancer cell), HO8901 (ovarian cancer cell), ECA109 (colon-cancer cell) plant into 4000/200 μ L/ holes on 96 orifice plates, every hole adds compound 2 μ L, final concentration is 12.0 μMs, 6.0 μMs, 3.0 μMs, 1.5 μMs, jointly in 37 DEG C, 5%CO
272 hours are hatched, with DMSO (1%) for blank in cell culture incubator.After 72 hours, add the MTT that final concentration is 0.25mg/mL, be placed in 37 DEG C, 5%CO
2in cell culture incubator 4 hours, blot solvent afterwards, every hole added 100 μ lDMSO, and measure absorbancy (OD value) with enzyme linked immunological instrument in 570nm place, the data obtained is for calculating IC
50value.Select the compound that inhibit activities is high, the compound effects time under different concns of the measuring different impact on human tumor cells cycle and apoptosis.
The test-compound of different concns carries out scalping with 96 orifice plates, according to the inhibiting rate of gained, calculates IC
50value, the results are shown in following table.
Norcantharidin derivative is to the IC of five kinds of tumor cell lines
50value
In a word, the foregoing is only preferred embodiment of the present invention, all equalizations done according to the present patent application the scope of the claims change and modify, and all should belong to the covering scope of patent of the present invention.
Claims (6)
1., containing chromone structure pyrazoles norcantharidin derivative, its general structure is as follows:
Wherein, R1 is H, OH, CH3, NO2, Cl or Br.
2. the preparation method containing chromone structure pyrazoles norcantharidin derivative according to claim 1, is characterized in that, comprise the steps:
Step 1): the synthesis of dehydronorcantharidiimide element: by MALEIC ANHYDRIDE porphyrize, add ether, be stirred under room temperature condition and dissolve completely, instillation furans, stirring at room temperature 24 ~ 48 hours, carries out filtration under diminished pressure by the product obtained after reacting completely and obtains Norcantharidin;
Step 2): the synthesis of N-substituted dehydronorcantharidiimide imide: be dissolved in acetone solvent by dehydronorcantharidiimide element, under agitation drips the acetone soln of aniline, reacts and adds manganese acetate, triethylamine and aceticanhydride after 1 hour, at room temperature reacts 8 hours; Precipitation after vacuum-drying is dissolved in dimethyl formamide, with dicyclohexylcarbodiimide stirring reaction 10 hours in ice-water bath, filtrate is placed in frozen water and obtains crystallization, then recrystallization obtains N-substituted dehydronorcantharidiimide imide;
Step 3): import chromone structure: be dissolved in dehydrated alcohol by N-substituted dehydronorcantharidiimide imide and 6-methyl substituted chromone phenylhydrazone, add chloramine-T, reflux 12 hours, carry out 1,3-Dipolar Cycloaddition, recrystallize, vacuum-drying obtains product.
3. the preparation method containing chromone structure pyrazoles norcantharidin derivative according to claim 2, is characterized in that: described step 2) in the temperature of ice-water bath be 0 DEG C.
4. the preparation method containing chromone structure pyrazoles norcantharidin derivative according to claim 2, is characterized in that: in described step 3), recrystallize adopts methyl alcohol.
5. the preparation method containing chromone structure pyrazoles norcantharidin derivative according to claim 2, it is characterized in that: the preparation method of described 6-methyl substituted chromone phenylhydrazone is as follows: get phenylhydrazine and add and fill in the flask of tetrahydrofuran (THF), boiling water bath return stirring is to dissolving, then the ethanol solution being dissolved with 6-methyl-chromone is slowly added dropwise to, continue boiling water bath return stirring, drip concentrated hydrochloric acid, pale yellow precipitate is had to occur, continuous boiling water bath return stirring 5h, stop water-bath, add distilled water to stir, pale yellow precipitate darkens, suction filtration obtains phenylhydrazone, yellowish red color needle-like product, rinse repeatedly with anhydrous diethyl ether, vacuum-drying obtains product 6-methyl-chromone phenylhydrazone.
6. arbitrary described containing the application of chromone structure pyrazoles norcantharidin derivative on synthesizing antineoplastic medicament according to claim 1-5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310574585.3A CN103554123B (en) | 2013-11-15 | 2013-11-15 | Containing chromone structure pyrazoles norcantharidin derivative and preparation method thereof and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310574585.3A CN103554123B (en) | 2013-11-15 | 2013-11-15 | Containing chromone structure pyrazoles norcantharidin derivative and preparation method thereof and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103554123A CN103554123A (en) | 2014-02-05 |
| CN103554123B true CN103554123B (en) | 2016-01-20 |
Family
ID=50008520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310574585.3A Expired - Fee Related CN103554123B (en) | 2013-11-15 | 2013-11-15 | Containing chromone structure pyrazoles norcantharidin derivative and preparation method thereof and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103554123B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106046019B (en) * | 2016-07-06 | 2018-07-17 | 绍兴文理学院 | A kind of Valine ring substituent norcantharidin derivative and the preparation method and application thereof |
| CN106083873B (en) * | 2016-07-06 | 2018-07-17 | 绍兴文理学院 | A kind of L-phenylalanine ring substituent norcantharidin derivative and the preparation method and application thereof |
| CN106188081B (en) * | 2016-07-06 | 2018-07-17 | 绍兴文理学院 | A kind of D-Val ring substituent norcantharidin derivative and the preparation method and application thereof |
| CN106083884B (en) * | 2016-07-06 | 2018-07-17 | 绍兴文理学院 | A kind of D-Leu ring substituent norcantharidin derivative and the preparation method and application thereof |
| CN106188080B (en) * | 2016-07-06 | 2018-08-10 | 绍兴文理学院 | A kind of D-phenylalanine ring substituent norcantharidin derivative and the preparation method and application thereof |
| CN106220642B (en) * | 2016-07-06 | 2018-09-14 | 绍兴文理学院 | A kind of L-Leu ring substituent norcantharidin derivative and the preparation method and application thereof |
| CN107602578B (en) * | 2017-11-07 | 2019-07-16 | 绍兴文理学院 | A kind of preparation method and applications of the D-Val ring substituent norcantharidin derivative of the structure containing pyridazinone |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002076989A1 (en) * | 2001-03-23 | 2002-10-03 | The University Of Newcastle Research Associates Limited | Protein phosphate inhibitors |
| CN101812066A (en) * | 2010-03-04 | 2010-08-25 | 绍兴文理学院 | Pyrazolo N-substituted dehydronorcantharidin imide derivative as well as synthesis method, activity test method and application thereof |
-
2013
- 2013-11-15 CN CN201310574585.3A patent/CN103554123B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002076989A1 (en) * | 2001-03-23 | 2002-10-03 | The University Of Newcastle Research Associates Limited | Protein phosphate inhibitors |
| CN101812066A (en) * | 2010-03-04 | 2010-08-25 | 绍兴文理学院 | Pyrazolo N-substituted dehydronorcantharidin imide derivative as well as synthesis method, activity test method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 1,3-Dipolar Cycloaddition Reaction: Synthesis of Novel 5,6-Dehydronorcantharidin Derivatives of Substituted Aromatic Amines with potential antitumor activities;L.-P. Deng，等;《J. Heterocyclic Chem.》;20050228;第42卷(第1期);第13-18页 * |
| 1,3-偶极环加成合成新型4,5-二氢-2,5-二氧杂吡咯啉并[4,5-c]异唑衍生物;刘方明，等;《有机化学》;20040531;第24卷(第5期);第521-524页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103554123A (en) | 2014-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103896954B (en) | A kind of pyrazoles norcantharidin derivative and preparation method thereof and application | |
| CN103554123B (en) | Containing chromone structure pyrazoles norcantharidin derivative and preparation method thereof and application | |
| CN103554122B (en) | A kind of containing chromone structure pyrazoles norcantharidin derivative and preparation method thereof and application | |
| CN103554135B (en) | A kind of containing chromone structure isoxazole norcantharidin derivative and preparation method thereof and application | |
| Reddy et al. | PEG-SO3H catalyzed synthesis and cytotoxicity of α-aminophosphonates | |
| CN106397445A (en) | Pyrazoles N-p-bromophenyl maleimide derivative containing chromone structure as well as preparation method and application thereof | |
| CN106810560B (en) | A kind of synthetic method of 8- azepine cumarin and its application in anti-tumor drug | |
| CN105924486B (en) | Triazole norcantharidin derivative of structure containing maltoside and the preparation method and application thereof | |
| CN102001979B (en) | Preparation method of 2-(2', 2'-difluoroethoxyl)-6-trifluoromethyl phenyl propyl sulfide | |
| CN111892608B (en) | Spiroheterocyclic 2, 3-dihydrobenzofuran compound with optical activity and application thereof | |
| CN103554134B (en) | Containing chromone structure isoxazole norcantharidin derivative and preparation method thereof and application | |
| CN105906678A (en) | Fluoro-substituted glucoside-structure-containing triazole norcantharidin derivative and preparation method and application thereof | |
| CN111100123B (en) | A process for preparing ellipticine or substituted ellipticine | |
| CN103739617B (en) | Isoxazole norcantharidin derivative and preparation method thereof and application | |
| CN106220642A (en) | A kind of L leucine ring substituent norcantharidin derivative and preparation method and application | |
| CN102268003B (en) | Unsymmetrical poly-substituted porphyrin gold (III) type anticancer compound and preparation method thereof | |
| CN106083967B (en) | Triazole norcantharidin derivative of structure containing Arabinoside and the preparation method and application thereof | |
| CN106008635A (en) | Triazole norcantharidin derivative containing galactoside structure, and preparation method and application thereof | |
| CN106083966A (en) | Fluorine replaces containing galactoside structure triazole norcantharidin derivative and preparation method and application | |
| CN114920684B (en) | Selenium-containing benzamide compound and synthetic method and application thereof | |
| CN106083965B (en) | Triazole norcantharidin derivative of structure containing lactoside and the preparation method and application thereof | |
| CN109988178B (en) | Pyrazole structure-containing N-p-nitrophenyl substituted maleimide alpha-terpinene cycloaddition derivative and preparation method and application thereof | |
| CN106046019A (en) | L-valine-substituted norcantharidin derivative and preparation method and application thereof | |
| CN106083968B (en) | Triazole norcantharidin derivative of structure containing glucoside and the preparation method and application thereof | |
| CN106632364A (en) | Pyrano[2,3-b]quinoline derivative as well as synthesis method and anti-tumor application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160120 Termination date: 20181115 |